Researchers at the Nanoscience Center (NSC) of University of Jyväskylä in Finland have developed a novel method to study enterovirus structures and their functions. The method will help to obtain new information on trafficking of viruses in cells and tissues as well as on the mechanisms of virus opening inside cells. This new information is important for example for developing new antiviral drugs and vaccines.
As if being sick weren't bad enough, there's also the fear of frequent injections, side effects and overdosing on you medication. Now a team of researchers from University of Copenhagen, Department of Chemistry, Nano- science center and the Institut Laue-Langevin (ILL), have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments.
MIT engineers have devised a way to measure the mass of particles with a resolution better than an attogram — one millionth of a trillionth of a gram. Weighing these tiny particles, including both synthetic nanoparticles and biological components of cells, could help researchers better understand their composition and function.
3D nanoSIMS project will provide high-resolution label-free imaging to reliably see where drugs go to in cells for the first time.
NantBioScience, subsidiary of NantWorks, LLC, a company focused on the discovery and development of innovative treatments for diseases with high unmet medical needs, today announced a strategic collaboration with Celgene to advance bold research programs to benefit cancer patients in need of new therapeutic solutions. As part of the transaction, Celgene will pay $75 million in funding to NantBioScience as an upfront option fee and equity investment.
Fabrus, Inc., a San Diego based antibody discovery company, announced today that it has obtained worldwide exclusive rights to Chimerasome™ nanocage technology originally developed by Chimeros, Inc.
Novavax, Inc. announced the continuation of their partnership with PATH to develop Novavax' RSV (respiratory syncytial virus) vaccine for maternal immunization. Under this amendment, PATH will provide Novavax approximately $3.5 million in funding to support the ongoing Phase II dose-confirmatory clinical trial in women of childbearing age, initiated in October 2013. Under this partnership, Novavax and PATH will also initiate planning activities for clinical development of the vaccine in low-resource countries.
Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer.
Researchers at Case Western Reserve University have received a $540,000 federal grant to devise methods for building minute structures tailored to precisely deliver medicines to tumors or carry dyes that help imaging technologies detect disease, create more efficient nanowires and nanoelectonics, and more.
According to a new market report published by Transparency Market Research "Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019,"the market for nanomedicine was valued at USD 78.54 billion in 2012 and is expected to reach a value of USD 177.60 billion in 2019, growing at a CAGR of 12.3% from 2013 to 2019.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.